Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q2 2020 · 10-Q
Revenue—
Net Income-$5.70M-$5.70MN/M vs Q2 2019 EPS Diluted-$0.36-$0.36N/M vs Q2 2019 Operating Income-$6,763,717N/M Operating Cash Flowderived-$7,083,058N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2020 · filed May 15, 2020 · 45 d after period end